This post hoc analysis of a randomized clinical trial investigates whether patient participation in clinical trials is associated with practitioner adherence to methicillin-resistant Staphylococcus au...

In the latest issue of JAMA, Johansen and colleagues1 report the results of a trial that investigated the impact of digital recruitment letter formats on recruitment to a larger clinical trial, the DA...

Hierarchical composite endpoints (HCEs) are increasingly being used in infectious diseases research. In this review aimed at educating the clinical reader,

This study by Pulia and colleagues1 reports results from a large population-based cohort using target trial emulation to examine the associations of antibiotic treatment with clinical outcomes in pati...

Shorter courses of antibiotic therapy are increasingly recommended to reduce antibiotic exposure. However, quantifying the real-world impact of duration of therapy is hindered by bias common in observational studies.

In this first-ever collaboration between Communicable and Breakpoints,...

Careers at The University of Melbourne

In 2010, the World Health Organization (WHO) increased recommended doses of first-line tuberculosis (TB) drugs for children.

Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontiè...

A major new clinical trial, the Streptococcal Adaptive Platform (STRAP), has received $5 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) to improve treatment for life-threatening streptococcal infections across all age groups. Lead by researchers and clinicians from the Doherty Institute, Murdoch Children's Research Institute (MCRI), and other national and international partners.